Avalo Therapeutics, Inc. (AVTX) Stock Profile — Insider Trades & Financials

Revenue$59.0K

Net Income-$13.7M

EPS$-5.47

Market Cap$328.4M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Garry Neil

CEO & Executive Director

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1Î², which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Founded: 2011
Employees: 23
Headquarters: Rockville, Maryland, United States
Website

⚡

Core Efficiency

ROE?

-16.52%

ROA?

-11.78%

D/E Ratio?

0.40

Op. Margin?

-33461.02%

📊

Profitability Ratios

Net Margin?

-23254.24%

Loading company sections...

Avalo Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness